
    
      Olaparib tablets will be taken twice daily, orally, in treatment cycles lasting 4 weeks.

      On days 1, 8, 12 and 22 of the first 2 cycles and day 1 of all other cycles, subjects will
      have a physical exam, be asked questions about their general health, and specific questions
      about any problems they might be having and any medications they are taking.

      Tumor will be assess by either CT or MRI scan every 2 cycles (every 2 months). Tumor biopsies
      will be optional in this study. Only participants that have received a PARP inhibitor in the
      past will be asked to have a biopsy of their tumor.
    
  